Windtree Therapeutics (WINT) Competitors $1.19 +0.14 (+13.33%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$1.19 +0.00 (+0.08%) As of 07/18/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock WINT vs. KZIA, CSCI, CVM, GOVX, MBIO, CYCN, PHXM, ARTL, SNSE, and LSBShould you be buying Windtree Therapeutics stock or one of its competitors? The main competitors of Windtree Therapeutics include Novogen (KZIA), COSCIENS Biopharma (CSCI), CEL-SCI (CVM), GeoVax Labs (GOVX), Mustang Bio (MBIO), Cyclerion Therapeutics (CYCN), PHAXIAM Therapeutics (PHXM), Artelo Biosciences (ARTL), Sensei Biotherapeutics (SNSE), and LakeShore Biopharma (LSB). These companies are all part of the "pharmaceutical products" industry. Windtree Therapeutics vs. Its Competitors Novogen COSCIENS Biopharma CEL-SCI GeoVax Labs Mustang Bio Cyclerion Therapeutics PHAXIAM Therapeutics Artelo Biosciences Sensei Biotherapeutics LakeShore Biopharma Novogen (NASDAQ:KZIA) and Windtree Therapeutics (NASDAQ:WINT) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, risk, earnings, valuation, institutional ownership and dividends. Which has stronger valuation & earnings, KZIA or WINT? Windtree Therapeutics has lower revenue, but higher earnings than Novogen. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNovogen$1.51M6.79-$17.56MN/AN/AWindtree TherapeuticsN/AN/A-$1.79M-$823.470.00 Which has more risk & volatility, KZIA or WINT? Novogen has a beta of 2.64, suggesting that its stock price is 164% more volatile than the S&P 500. Comparatively, Windtree Therapeutics has a beta of 0.7, suggesting that its stock price is 30% less volatile than the S&P 500. Do analysts rate KZIA or WINT? Novogen currently has a consensus price target of $14.00, indicating a potential upside of 37.93%. Windtree Therapeutics has a consensus price target of $350.00, indicating a potential upside of 29,311.76%. Given Windtree Therapeutics' higher possible upside, analysts plainly believe Windtree Therapeutics is more favorable than Novogen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Novogen 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50Windtree Therapeutics 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Is KZIA or WINT more profitable? Novogen's return on equity of 0.00% beat Windtree Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets NovogenN/A N/A N/A Windtree Therapeutics N/A -227.93%-56.46% Do institutionals & insiders believe in KZIA or WINT? 30.9% of Novogen shares are held by institutional investors. Comparatively, 29.3% of Windtree Therapeutics shares are held by institutional investors. 1.0% of Novogen shares are held by insiders. Comparatively, 0.3% of Windtree Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Does the media prefer KZIA or WINT? In the previous week, Novogen had 1 more articles in the media than Windtree Therapeutics. MarketBeat recorded 6 mentions for Novogen and 5 mentions for Windtree Therapeutics. Windtree Therapeutics' average media sentiment score of 0.48 beat Novogen's score of 0.37 indicating that Windtree Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novogen 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Windtree Therapeutics 1 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryNovogen beats Windtree Therapeutics on 10 of the 13 factors compared between the two stocks. Get Windtree Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for WINT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding WINT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart WINT vs. The Competition Export to ExcelMetricWindtree TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.36M$2.94B$5.54B$9.43BDividend YieldN/A2.48%4.00%4.03%P/E Ratio0.0019.8828.2619.77Price / SalesN/A292.06410.8187.35Price / CashN/A41.8435.8558.18Price / Book0.037.678.115.65Net Income-$1.79M-$55.28M$3.25B$257.97M7 Day Performance63.01%4.87%1.64%3.75%1 Month Performance116.36%11.73%7.28%11.53%1 Year Performance-99.34%3.72%33.14%19.22% Windtree Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)WINTWindtree Therapeutics2.9956 of 5 stars$1.19+13.3%$350.00+29,311.8%-99.4%$4.36MN/A0.0030News CoverageGap UpHigh Trading VolumeKZIANovogen3.697 of 5 stars$11.43+5.8%$14.00+22.5%-65.8%$11.54M$1.51M0.0012Gap DownCSCICOSCIENS BiopharmaN/A$3.62+2.5%N/AN/A$11.39M$9.03M-0.6220Positive NewsGap DownCVMCEL-SCI0.1215 of 5 stars$3.63+2.8%N/A-90.4%$11.01MN/A-7.5643High Trading VolumeGOVXGeoVax Labs2.2302 of 5 stars$0.69+1.4%$11.10+1,520.2%-74.0%$10.91M$3.95M-0.1910Analyst ForecastMBIOMustang Bio0.7161 of 5 stars$2.42-8.7%N/A-87.2%$10.60MN/A-0.03100Analyst UpgradeGap DownCYCNCyclerion Therapeutics0.9436 of 5 stars$3.30-9.3%N/A+21.2%$10.59M$2M-2.8430Gap UpPHXMPHAXIAM TherapeuticsN/A$3.10flatN/AN/A$10.58MN/A0.0049News CoverageARTLArtelo Biosciences2.1219 of 5 stars$18.55-22.3%$25.00+34.8%+75.5%$10.20MN/A-1.035Gap UpSNSESensei Biotherapeutics4.3569 of 5 stars$8.08-1.1%$90.00+1,013.9%-41.6%$10.19MN/A-0.3540News CoveragePositive NewsLSBLakeShore Biopharma0.3516 of 5 stars$1.11+2.8%N/A-79.2%$10.05M$80.82M0.00773Gap Up Related Companies and Tools Related Companies KZIA Competitors CSCI Competitors CVM Competitors GOVX Competitors MBIO Competitors CYCN Competitors PHXM Competitors ARTL Competitors SNSE Competitors LSB Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:WINT) was last updated on 7/19/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Windtree Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Windtree Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free WINT Stock Alerts